Biotech Hot Potato

When drugmakers play hot potato after a drug fails, the original rights holder usually ends up holding the spud.

Aeterna Zentaris (Nasdaq: AEZS  ) is hoping to make a baked potato.

The biotech said yesterday that it had regained North American rights to perifosine, its cancer drug that was being developed by Keryx Biopharmaceuticals (Nasdaq: KERX  ) until it failed to show an effect in colorectal cancer.

The drug is still in a phase 3 trial for multiple myeloma testing in combination with Velcade sold by Takeda and Johnson & Johnson (NYSE: JNJ  ) and a generic called dexamethasone compared with Velcade and dexamethasone alone. Aeterna Zentaris said it plans to continue that trial and Keryx will get low single-digit royalties if the drug is eventually approved in North America.

It's a little hard to know whether continuing the trial is worth the money. Certainly there are plenty of drugs that have worked with one cancer type but not another -- Pfizer's (NYSE: PFE  ) Sutent is a prime example -- but there are also plenty of drugs that haven't worked on any cancer. Without knowing the cost of continuing the trial or the likelihood of success, which is probably quite low given Keryx's decision, it's not clear whether Aeterna Zentaris is just throwing good money after bad or making a reasonable high-risk, high-reward bet.

It's also not certain how long it will take to run the trial. Keryx said the recruitment for the multiple myeloma trial has been "difficult," and that's not likely to get any easier after doctors heard about the failure in colorectal cancer. There are a couple of interim peeks at the data scheduled, and reading between the lines, it looks like Aeterna Zentaris might be planning to drop the drug at that point if it doesn't seem like perifosine works in multiple myeloma.

Only time will tell whether continuing the trial is a good move for Aeterna Zentaris. While you wait, I certainly wouldn't give the biotech any value for reacquiring perifosine.

Looking for more high-tech stock ideas? Check out the Fool's free report, "3 Hidden Winners of the iPhone, iPad, and Android Revolution" where you'll find three companies quietly cashing in on the booming smartphone and tablet PC markets. Get your free copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1882600, ~/Articles/ArticleHandler.aspx, 9/1/2014 9:31:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement